RUNX1 and non-small cell lung carcinoma: Macrophage‐specific and systemic inhibition of Runx1 effectively blocks MMT‐driven tumor formation in vivo, representing a druggable therapeutic target to eliminate tumor‐promoting CAFs in NSCLC patients.